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Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering
real-world implementation practices, and their evolution over time. Modern cancer therapeutics are approved as
single agents oftentimes compared to the least active approved standard agent in randomized trials. However, the
burgeoning diversity and number of drugs introduces a complexity that quickly outstrips the knowledge provided
by these pivotal trials. This gap in information is particularly relevant when survival is the primary therapeutic
endpoint. In addition, the inherent complexity of the immune response will make registries a particularly important
tool in expeditiously understanding solid tumor immunotherapy and patient outcomes.
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A registry is a structured collection of observational
data, records, and/or laboratory specimens that can be
collected retrospectively, prospectively, or both. The spe-
cific goals of each registry vary from storing clinically
qualified specimens to studying safety, patient-reported
outcomes, or cost effectiveness. Registries may study the
use of a particular therapy across diseases or a specific
disease independent of a therapy. Unlike classic thera-
peutic studies, instructions regarding treatment adminis-
tration are not fixed in the registry protocol and their
variation is a legitimate study target. Registries may have
liberal inclusion criteria but often share attributes of a
formal clinical trial such as IRB approval, patient con-
sent and site compensation for data entry. A broad cross
section of participating centers spanning academic and
community sites is typically included in registries.
Registries fundamentally differ from disease databases.
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gram are large disease-centric databases that passively col-
lect patient demographics, death rates, and therapy
history [1,2]. A therapy-specific registry collects additional
data aiming to define and change treatment paradigms
and positively impact patient morbidity, quality of life, and
survival. The longitudinal follow-up of a broad patient
population treated in a real world setting exposes rare or
late toxicities, serves as source material to help generate
hypotheses about optimal sequencing or combination of
therapies, permits assessment of subject outcomes, and al-
lows for prospective testing and validation of novel ideas.
Registries also have an advantage over randomized clinical
trials since they continually update and permit real-time
analysis to address questions as they arise. Thus, registries
occupy a unique but critical position in oncology care.
Therapy-specific registries have a track record of trans-
forming medical practice. The Center for International
Bone Marrow Transplant Registry (CIBMTR) is the proto-
type for how a registry globally influenced the evolution of
a therapy and positively impacted patient outcomes [3,4].
Specific examples of CIBMTR’s influence include; the
refinement of preparative regimens, the supportive mea-
sures necessary to maintain the patient during neutro-
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age graft versus host disease, the value of transplanting in
remission and the use of unrelated donors. Outcomes
continued to improve and transplant use increased despite
tectonic shifts in indications for BMT, and the advent of
oral targeted therapy (i.e. imatinib, dasatinib) for diseases
previously only treatable with transplant.
A disease-specific registry for mRCC, The Inter-
national Metastatic Renal-Cell Cancer Database Consor-
tium (IMRDC) has published a number of reports since
2009 regarding prognostic models, sequencing of agents,
and conditional survival for treatment with targeted ther-
apy agents [5-7]. A unique feature of mRCC therapy has
been the rapid introduction of multiple agents of similar
class. The IMRDC registry observed that no meaningful
differences in survival are associated with any particular
sequence of VEGF and mTOR targeted therapies [6], yet
at least 4 randomized clinical trials have been performed
demonstrating this point [8-11].
Clearly there are limitations to registries. Retrospective
data can be biased in multiple ways including: noncon-
secutive patient selection, lower performance status pa-
tients may opt out of entering the study, heterogeneous
patient populations, differences in practice patterns, var-
iations in documentation and data abstraction, and ab-
sence of adjustments for subsequent treatments which
might affect overall survival. All these potential pitfalls
were considered in the construction and conduct of the
interleukin-2 (IL-2) registry discussed below.
Interleukin-2 immunotherapy is a high impact registry
opportunity
Cancer immunotherapy, such as HD IL-2, consistently de-
livers durable long term, therapy-free responses. The com-
bination and concurrent use of emergent new therapies
may enhance but also potentially threaten this curative
potential. There is a critical knowledge gap about how
best to sequence new drugs or to incorporate them into
existing therapy choices to maximize long term patient
outcomes. Immune checkpoint inhibitors add another
potentially curative therapy whose interaction with IL-2
and other therapies is complex. Long-term survival and
toxicity data are already available for IL-2, thus providing
a reference point against which to interpret the impact
of new therapies in sequence or combination. Further-
more, the availability of HD IL-2 therapy is limited by
the highly technical nature of its administration due to
its toxicity [12,13]. A registry is an important resource
in helping establish best practices for IL-2 therapy as
new agents are improved for the treatment of melan-
oma and renal cell carcinoma.
With these aims firmly in mind, the Proleukin® Obser-
vational Registry to Evaluate the Treatment Patterns and
Clinical Response in Malignancy (PROCLAIMSM)(www.proclaimregistry.com) was created in 2011, with both
retrospective and prospective cohorts. PROCLAIM es-
tablishes a clinical database on patients diagnosed with
advanced kidney cancer (mRCC) and melanoma (mM)
who are treated with HD IL-2 [14]. Data points include:
patient demographics, peri-treatment adverse events and
management, other therapies, prior, during and after the
IL-2. Outcomes, including long term survival will be col-
lected. A major goal of PROCLAIM is to serve as a re-
source for interested investigators to generate new ideas
and to answer high priority scientific and clinical ques-
tions. Presently, there are over 35 sites participating in
the PROCLAIM Registry and over 900 patients enrolled.
PROCLAIM has generated a number of national meet-
ing presentations [15,16] and recently released its second
Annual Report [17]. Analyses with regards to toxicity,
response rates, outcomes and optimal drug sequence are
in progress. These will have significant impact on patient
selection, toxicity management and most importantly,
the ‘cure’ rate for these cancers.
Conclusion
Efficiently refining the role of marketed cancer therapeu-
tics demands that investigators generate hypotheses with
the greatest potential for decisive answers and ‘real-life’
clinical utility. We believe that this can only be achieved
by registries, including PROCLAIM, real-time, real-use
sources of structured information which supply the raw
data from which testable hypotheses arise. PROCLAIM
serves this critical role by providing the data from which
any interested investigator could generate new questions
about high dose IL-2 therapy, including those that will
establish modern benchmarks for outcomes and create
best practices. Structured to support a productive collab-
oration between industry, academia, and community
practice, PROCLAIM will serve as a model for other
registries in rapidly evolving areas of oncology therapeu-
tics where there is a pressing need to integrate more
established drugs with new therapeutics.
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